PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications ...
ROCKVILLE, MD, USA I January 6, 2025 I I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision ...
Under the terms of the agreement, the licensee will obtain rights to develop, secure regulatory approval for, and commercialize SPD8 in the designated market. The licensing agreement includes ...
SOUTH SAN FRANCISCO, CA, USA I January 06, 2025 I Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the ...
SAN DIEGO, CA, USA & SHANGHAI, China I January 06, 2024 I Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company focused on becoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback